MEIP
MEI Pharma Inc
$
6.740
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.870
Open
6.600
VWAP
6.47
Vol
590.33K
Mkt Cap
201.39M
Low
6.210
Amount
3.82M
EV/EBITDA(TTM)
--
Total Shares
6.66M
EV
180.92M
EV/OCF(TTM)
--
P/S(TTM)
--
MEI Pharma, Inc. is a pharmaceutical company, which is engaged in developing cancer therapies. The Company’s pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor. Voruciclib has completed a Phase I trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) in combination with the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax (marketed as Venclexta). Voruciclib is also being evaluated in pre-clinical studies to explore potential activity in various solid tumor cancers including in combination with therapies that target the RAS signaling pathway, such as KRAS inhibitors. CDK9 has functions in cell cycle regulation, including the modulation of two therapeutic targets in cancer: myeloid leukemia cell differentiation protein (MCL1) and the MYC proto-oncogene protein (MYC) which regulates cell proliferation and growth.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q4
0.00
-100%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for MEI Pharma, Inc. (MEIP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 238.69%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+238.69%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for MEI Pharma Inc (MEIP.O) is -1.07, compared to its 5-year average forward P/E of -2.11. For a more detailed relative valuation and DCF analysis to assess MEI Pharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.11
Current PE
-1.07
Overvalued PE
0.26
Undervalued PE
-4.48
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
47.63
Current PS
0.00
Overvalued PS
180.08
Undervalued PS
-84.83
Financials
Annual
Quarterly
FY2025Q3
0.00
Total Revenue
FY2025Q3
YoY :
-71.78%
-2.77M
Operating Profit
FY2025Q3
YoY :
-71.81%
-2.57M
Net Income after Tax
FY2025Q3
YoY :
-71.53%
-0.39
EPS - Diluted
FY2025Q3
YoY :
+11.58%
-3.27M
Free Cash Flow
FY2025Q3
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q3
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q3
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MEIP News & Events
Events Timeline
2025-07-18 (ET)
2025-07-18
08:39:18
MEI Pharma to sell 29.24M shares at $3.42 in private placement
2025-05-13 (ET)
2025-05-13
16:08:39
MEI Pharma reports Q3 EPS (39c) vs ($1.37) last year
2024-11-12 (ET)
2024-11-12
15:21:42
MEI Pharma reports Q1 EPS ($1.20) vs. $8.46 last year
Sign Up For More Events
Sign Up For More Events
News
4.5
07-21BenzingaUS Stocks Likely To Open Higher Despite Trump Administration's 'Hard Deadline' Warning For Tariffs — Verizon, Domino's Pizza Earnings In Focus
8.5
07-18BenzingaWhy Is MEI Pharma Stock Soaring On Friday?
4.5
07-18BenzingaDow Falls Over 200 Points; 3M Earnings Top Views
Sign Up For More News
People Also Watch
BFRG
Bullfrog AI Holdings Inc
1.520
USD
-3.80%
CARM
Carisma Therapeutics Inc
0.388
USD
-1.52%
DFLI
Dragonfly Energy Holdings Corp
0.409
USD
+12.04%
LOCL
Local Bounti Corp
2.970
USD
+1.37%
ADN
Advent Technologies Holdings Inc
1.990
USD
-5.69%
OCEA
Ocean Biomedical Inc
0
USD
-87.80%
SANW
S&W Seed Co
1.770
USD
-3.54%
PWM
Prestige Wealth Inc
0.435
USD
-1.14%
ELSE
Electro-Sensors Inc
4.760
USD
-1.86%
COEP
Coeptis Therapeutics Holdings Inc
11.630
USD
-2.35%
FAQ
What is MEI Pharma Inc (MEIP) stock price today?
The current price of MEIP is 6.74 USD — it has increased 2.12 % in the last trading day.
What is MEI Pharma Inc (MEIP)'s business?
What is the price predicton of MEIP Stock?
What is MEI Pharma Inc (MEIP)'s revenue for the last quarter?
What is MEI Pharma Inc (MEIP)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for MEI Pharma Inc (MEIP)'s fundamentals?
How many employees does MEI Pharma Inc (MEIP). have?